Inthera Bioscience, a Zürich, Switzerland-based biopharmaceutical company focused on the development of small molecule therapies for solid tumors, raised $3.7m (€3.4m) seed funding round.
The round was led by MS Ventures, with equal participation from Aglaia BioMedical Ventures’ Aglaia Oncology Fund II and Danish Novo Seeds as well as EVA Basel.
The company intends to use the funds to advance its lead program from in vivo proof of concept to the clinic and expand its emerging pipeline.
Founded in 2013 by Dr. Ulrich Kessler and Prof. Paramjit Arora, Inthera Bioscience employs a proprietary technology platform to rationally design protein-protein interaction inhibitors. The company has discovered disruptors of hypoxia-inducible signaling for the treatment of solid tumors and targeted agents against HPV- associated cancer, which are in pre-clinical development.